GlobeNewsWire
24 Mar 2026, 20:05 UTC · 33w ago
Verdict
Headline takes no side. We score BCDA +0.40 — moderately bullish.
+0.40moderately bullish
More positive than 69% of ticker scores this week
Scored by the NIS engine · methodology.
Which stocks this story touches
More positive than 69% of ticker scores this week
The company is reporting business highlights, advancing clinical trials, and pursuing regulatory clearances for its cell therapy platforms.
Continue reading
5 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
39m ago
−31.7%
Price is moving against the score
$0.8260 vs $1.21 close before publication (Mar 24) · not market-adjusted
BCDA chart →
